First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Participants
Objective: To evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses (SAD/MAD) of ARV-102, a PROteolysis TArgeting Chimera (PROTAC) leucine-rich…Rapid Neurologic Decline after Subthalamic Nucleus Deep Brain Stimulation in Leucine-Rich Repeat Kinase 2 Parkinson’s disease (LRRK2-PD)
Objective: To describe the clinical outcomes of two unrelated patients with LRRK2-PD who experienced rapid neurologic decline following subthalamic nucleus deep brain stimulation (STN-DBS). Background:…LRRK2 Pathway Inhibition By NEU-411, a Potent, Selective, CNS-Penetrant LRRK2 Inhibitor In Healthy Participants
Objective: The aim of this work was to evaluate LRRK2 pathway modulation by the potent, selective, CNS-penetrant LRRK2 inhibitor NEU-411 in healthy adults and elderly…Familial parkinson disease A comparative study between LRRK2 and PINK 1 mutations
Objective: Describe the clinical phenotypes of monogenic forms of PD linked to LRRK2 and PINK1 mutations with a view to a comparative study between the…LRRK2 antisense oligonucleotide (BIIB094/ION859) impact on cerebrospinal fluid biomarkers in Parkinson’s disease patients
Objective: To provide novel fluid biomarker results from REASON – a Phase 1 clinical trial testing a LRRK2 antisense oligonucleotide in both LRRK2-Parkinson’s disease and…Analysis of LRRK2 Exonic Variants in Parkinson’s Disease in Chinese Population
Objective: To investigate the frequency of multiple LRRK2 variants in Parkinson's disease (PD) cohort, and to explore the effect of LRRK2 variants on the occurrence…Investigating the cellular consequences of the G2385R LRRK2 variant
Objective: The objective of this study is to characterise the biochemical and cellular impact of the G2385R coding variant in LRRK2, a risk variant for…Association of sequence alterations in the promoter region of the RAB7L1 gene with lysosomal hydrolase activity in blood and reduced risk of Parkinson disease
Objective: The aim of this case-control study was to examine the association between SNPs located in the promoter region of the RAB7L1 gene and Parkinson's…Lysosomal Lipid Dysregulation in Parkinson’s Disease: Genetic and Medication Effects in CSF Metabolomics
Objective: Define lipid signatures in sporadic, LRRK2, and GBA1 PD and pre-manifest carriers and assess medication impacts. Background: Lysosomal dysfunction contributes to PD, particularly in…Large-scale genetic characterization of Parkinson’s disease in the African and African admixed populations
Objective: The influence of genetics has been primarily studied in European populations, limiting our understanding of the genetic landscape of PD in the African and…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 19
- Next Page »